Literature DB >> 22972572

Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

Bess Levin1, Denise Lech, Bernard Friedenson.   

Abstract

Inheriting a BRCA1 or BRCA2 gene mutation can cause a deficiency in repairing complex DNA damage. This step leads to genomic instability and probably contributes to an inherited predisposition to breast and ovarian cancer. Complex DNA damage has been viewed as an integral part of DNA replication before cell division. It causes temporary replication blocks, replication fork collapse, chromosome breaks and sister chromatid exchanges (SCEs). Chemical modification of DNA may also occur spontaneously as a byproduct of normal processes. Pathways containing BRCA1 and BRCA2 gene products are essential to repair spontaneous complex DNA damage or to carry out SCEs if repair is not possible. This scenario creates a theoretical limit that effectively means there are spontaneous BRCA1/2-associated cancers that cannot be prevented or delayed. However, much evidence for high rates of spontaneous DNA mutation is based on measuring SCEs by using bromodeoxyuridine (BrdU). Here we find that the routine use of BrdU has probably led to overestimating spontaneous DNA damage and SCEs because BrdU is itself a mutagen. Evidence based on spontaneous chromosome abnormalities and epidemiologic data indicates strong effects from exogenous mutagens and does not support the inevitability of cancer in all BRCA1/2 mutation carriers. We therefore remove a theoretical argument that has limited efforts to develop chemoprevention strategies to delay or prevent cancers in BRCA1/2 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972572      PMCID: PMC3521784          DOI: 10.2119/molmed.2012.00280

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  74 in total

Review 1.  Analysis of intrachromosomal homologous recombination in mammalian cell, using tandem repeat sequences.

Authors:  S Lambert; Y Saintigny; F Delacote; F Amiot; B Chaput; M Lecomte; S Huck; P Bertrand; B S Lopez
Journal:  Mutat Res       Date:  1999-04-09       Impact factor: 2.433

2.  Sister chromatid exchange (SCE) and high-frequency cells (HFC) in peripheral blood lymphocytes of healthy Tunisian smokers.

Authors:  Ghada Ben Salah; Hassen Kamoun; Ahmed Rebai; Achraf Ben Youssef; Hajer Ayadi; Neila Belghith-Mahfoudh; Amine Fourati; Hamadi Ayadi; Faiza Fakhfakh
Journal:  Mutat Res       Date:  2010-09-29       Impact factor: 2.433

3.  Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.

Authors:  Hormuzd A Katki; Mitchell H Gail; Mark H Greene
Journal:  Lancet Oncol       Date:  2007-12       Impact factor: 41.316

Review 4.  Base-excision repair of oxidative DNA damage.

Authors:  Sheila S David; Valerie L O'Shea; Sucharita Kundu
Journal:  Nature       Date:  2007-06-21       Impact factor: 49.962

5.  Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Authors:  S M Domchek; M M Gaudet; J E Stopfer; M H Fleischaut; J Powers; N Kauff; K Offit; K L Nathanson; M Robson
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

6.  Age-dependent accumulation of recombinant cells in the mouse pancreas revealed by in situ fluorescence imaging.

Authors:  Dominika M Wiktor-Brown; Carrie A Hendricks; Werner Olipitz; Bevin P Engelward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-01       Impact factor: 11.205

7.  Gamma-tocopherol is less effective than alpha-tocopherol in preventing oxidant-induced sister chromatid exchanges in Chinese hamster V79 cells.

Authors:  K A O'Leary; J A Woods; N M O'Brien
Journal:  Free Radic Res       Date:  2001-12

8.  Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors.

Authors:  T Focken; D Steinemann; B Skawran; W Hofmann; P Ahrens; N Arnold; P Kroll; H Kreipe; B Schlegelberger; D Gadzicki
Journal:  Cytogenet Genome Res       Date:  2011-10-24       Impact factor: 1.636

9.  p53 null fluorescent yellow direct repeat (FYDR) mice have normal levels of homologous recombination.

Authors:  Dominika M Wiktor-Brown; Michelle R Sukup-Jackson; Saja A Fakhraldeen; Carrie A Hendricks; Bevin P Engelward
Journal:  DNA Repair (Amst)       Date:  2011-10-12

10.  A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest.

Authors:  Zhihui Feng; Junran Zhang
Journal:  Nucleic Acids Res       Date:  2011-09-27       Impact factor: 16.971

View more
  4 in total

Review 1.  Mutations in components of antiviral or microbial defense as a basis for breast cancer.

Authors:  Bernard Friedenson
Journal:  Funct Integr Genomics       Date:  2013-09-21       Impact factor: 3.674

2.  An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.

Authors:  Ewa Przybytkowski; Thomas Davis; Abdelrahman Hosny; Julia Eismann; Ursula A Matulonis; Gerburg M Wulf; Sheida Nabavi
Journal:  BMC Cancer       Date:  2020-03-12       Impact factor: 4.430

3.  PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.

Authors:  Xusheng Bai; Enke Zhang; Hua Ye; Vijayalakshmi Nandakumar; Zhuo Wang; Lihong Chen; Chuanning Tang; Jianhui Li; Huijin Li; Wei Zhang; Wei Han; Feng Lou; Dandan Zhang; Hong Sun; Haichao Dong; Guangchun Zhang; Zhiyuan Liu; Zhishou Dong; Baishuai Guo; He Yan; Chaowei Yan; Lu Wang; Ziyi Su; Yangyang Li; Lindsey Jones; Xue F Huang; Si-Yi Chen; Jinglong Gao
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

4.  Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'.

Authors:  Bernard Friedenson
Journal:  Br J Cancer       Date:  2016-07-26       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.